Traders should now look for long-biased trades in BGMD as long as it's trending above some key near-term support levels at $1.60 to $1.56 and then once it sustains a move or close above those breakout levels with volume that hits near or above 255,357 shares. If that breakout triggers soon, then BGMD will set up to re-test or possibly take out its next major overhead resistance levels at $2.30 to $2.53. Any high-volume move above $2.53 will then put its 200-day at $2.69 to $3 into range for shares of BGMD. Synergy ResourcesSynergy Resources ( SYRG) is an exploration stage company engaged in oil and gas acquisitions, exploration, development and production activities. This stock closed up 4.4% to $6.80 on Tuesday. Tuesday's Range: $6.54-$6.80 52-Week Range: $2.40-$7.78 Volume: 130,000 Three-Month Average Volume: 254,095 >>XXX From a technical perspective, SYRG bounced higher here right above some near-term support at $6.37 with lighter-than-average volume. This stock has been finding buying interest over the last month and change, each time it's pulled back near $6.20. Shares of SYRG are now quickly moving within range of triggering a near-term breakout trade. That trade will hit if SYRG manages to take out its 50-day at $6.85 and then once it clears some more near-term overhead resistance levels at $6.80 to $7 with high volume. Traders should now look for long-biased trades in SYRG as long as it's trending above its 50-day at $6.84 or above some key near-term support at $6.37 and then once it sustains a move or close above those breakout levels with volume that hits near or above 254,095 shares. If that breakout triggers soon, then SYRG will set up to re-test or possibly take out its next major overhead resistance levels at $7.53 to $7.78. Any high-volume move above $7.78 will then push shares of SYRG into new 52-week high territory, which is bullish technical price action. Accelerate DiagnosticsAccelerate Diagnostics ( AXDX) develops BACcel system, planned for rapid diagnosis in life-threatening bacterial infections. It has also developed and out-licensed OptiChem surface coatings for use in microarraying components. This stock closed up 7.7% to $8.24 on Tuesday.
Sunshine Heart (SSH) plunges after the company, known for its C-Pulse Heart Assist System to treat moderate to severe heart failure, reported a fourth-quarter loss per share that was wider than analysts' expectations and also provided a discouraging update on a pivotal trial. The company noted a loss of 42 cents a share, wider than the consensus estimate of 40 cents a share. Sunshine Heart reported no revenue, as expected. Sunshine Heart also provided an update on its pivotal C-Pulse® COUNTER HF U.S. investigational study and noted the activation of eight sites with a total of 24 additional sites committed to participate, which increases the total number to 32. The company reported in January 2014 that one additional patient had enrolled in the trial for a total of three patients through year-end. Unfortunately, the pace of enrollment in the trials has been extremely slow. The trial, which would have an estimated enrollment of 388, began in Nov. 2012 and has an estimated data collection date of April 2016 and an estimated study completion date of April 2017.